# Complex Medium-Chain Triglycerides Mitigate Porcine Epidemic Diarrhea Virus Infection in Piglets by Enhancing Anti-Inflammation, Antioxidation, and Intestinal Barrier Function

**Authors:** Tingting Hu, Yunhao Liu, Sihui Gao, Xiaonan Zhao, Huangzuo Cheng, Youjun Hu, Huaqiao Tang, Zhiwen Xu, Chunlin Fang

PMC · DOI: 10.3390/v17070920 · 2025-06-27

## TL;DR

Complex medium-chain triglycerides help reduce PEDV infection in piglets by improving immune response, reducing inflammation, and supporting gut health.

## Contribution

This study demonstrates that CMCTs, a natural compound, can effectively mitigate PEDV infection through multiple biological mechanisms.

## Key findings

- CMCT treatment reduced clinical signs and weight loss in PEDV-infected piglets.
- CMCTs enhanced anti-inflammatory and antioxidant responses while restoring intestinal barrier function.
- Gut microbiota composition was modulated, increasing beneficial bacteria and decreasing pathogens.

## Abstract

Porcine epidemic diarrhea (PED), a highly contagious enteric disease caused by the porcine epidemic diarrhea virus (PEDV), is characterized by vomiting, diarrhea, and dehydration, leading to high mortality in newborn piglets and significant economic losses in the swine industry. The shortage of effective PED vaccines emphasizes the need to explore potent natural compounds for therapeutic intervention. It has been shown that glycerol monolaurate (GML) effectively inhibits PEDV replication in vivo and in vitro. Further investigation is needed to assess whether complex medium-chain triglycerides (CMCTs), composed of glyceryl tricaprylate/caprate (GTCC) and GML, offer an efficient anti-PEDV activity. In this study, piglets were orally infected with PEDV and exhibited typical clinical signs, including diarrhea and vomiting, accompanied by intestinal inflammation, oxidative stress, and tissue damage. CMCTs were administered orally twice daily for one week. In vivo findings indicate that CMCT treatment alleviated clinical signs and prevented weight loss. It significantly increased serum immunoglobulins (IgG, IgM, and IgA) and intestinal mucosal sIgA and MUC-2 levels, while reducing pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, and IL-17) and increasing antiviral interferons (IFN-α and IFN-γ), anti-inflammatory cytokines (IL-4 and IL-10), and IL-22. Antioxidant enzyme activities (T-AOC, SOD, GSH-Px, and CAT) were elevated, whereas oxidative stress markers (iNOS, NO, and MDA) were decreased. Expression of intestinal tight junction proteins claudin-1 and ZO-1 was restored. Moreover, CD4+ and CD8+ T cell populations increased, and the functions of regulatory T cells (Tregs) were restored. Gut microbiota analysis showed increased beneficial genera (Streptococcus and Ligilactobacillus) and decreased pathogenic Escherichia-Shigella. These results demonstrate that CMCTs mitigate PEDV infection by enhancing anti-inflammation, antioxidation, and intestinal barrier function, as well as modulating gut microbiota composition. This study improves the understanding of the pathogenesis of PEDV and highlights CMCTs as a promising therapeutic candidate for PED.

## Linked entities

- **Proteins:** CLDN7 (claudin 7), TJP1 (tight junction protein 1)
- **Chemicals:** glycerol monolaurate (PubChem CID 14871), glyceryl tricaprylate/caprate (PubChem CID 131739815)
- **Diseases:** PED (MONDO:0012805)
- **Species:** Sus scrofa (taxon 9823)

## Full-text entities

- **Genes:** CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, ISYNA1 (inositol-3-phosphate synthase 1) [NCBI Gene 51477] {aka INO1, INOS, IPS, IPS 1, IPS-1}, IL22 (interleukin 22) [NCBI Gene 50616] {aka IL-21, IL-22, IL-D110, IL-TIF, ILTIF, TIFIL-23}, CAT (catalase) [NCBI Gene 847], IFNA1 (interferon alpha 1) [NCBI Gene 3439] {aka IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, MUC2 (mucin 2, oligomeric mucus/gel-forming) [NCBI Gene 4583] {aka MLP, MUC-2, SMUC}, TJP1 (tight junction protein 1) [NCBI Gene 7082] {aka ZO-1}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, CLDN1 (claudin 1) [NCBI Gene 9076] {aka CLD1, ILVASC, SEMP1}
- **Diseases:** diarrhea (MESH:D003967), dehydration (MESH:D003681), weight loss (MESH:D015431), PED (MESH:D019318), infection (MESH:D007239), Inflammation (MESH:D007249), vomiting (MESH:D014839), enteric disease (MESH:D004751), inflammatory cytokines (MESH:D000080424)
- **Chemicals:** GML (MESH:C020777), Medium-Chain Triglycerides (MESH:C000709826), CMCT (-), NO (MESH:D009614), MDA (MESH:D015104)
- **Species:** Streptococcus (genus) [taxon 1301], Sus scrofa (pig, species) [taxon 9823], Porcine epidemic diarrhea virus (no rank) [taxon 28295]

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12299936/full.md

---
Source: https://tomesphere.com/paper/PMC12299936